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Acute decompensated heart failure
A B S T R A C T
Background: There is a link between sympathetic overactivity and sleep-disordered breathing (SDB), and
both of which are important indicators of the development of heart failure. To manage the increasing
numbers of heart failure patients, any method used to check for them needs to be as non-invasive,
simple, and cost-effective as possible. The purpose of this study is to assess screening of SDB with a non-
restrictive monitor and the autonomic nervous system in heart failure patients.
Methods: The subjects were 49 patients (mean age: 67 years; male: 78%) hospitalized for worsening
heart failure. After stabilization with appropriate medical therapy, each patient simultaneously
underwent sleep apnea syndrome (SAS) screening with the SD-101 (Kenzmedico Co. Ltd., Saitama,
Japan), which is a novel, non-restrictive, sheet-like monitor for SAS screening, and assessment of heart
rate variability (HRV) with a Holter monitor. In addition, we assessed daytime sleepiness by using the
Epworth Sleepiness Scale.
Results: The mean respiratory disturbance index (RDI) was 21.9 events/h. Males had signiﬁcantly greater
RDI values than females (24.5  11.2 events/h vs. 13.0  6.2 events/h, p < 0.001). RDI on SD-101 testing
was closely correlated with cyclic variation of heart rate index obtained with a Holter electrocardiogram
scanner (r = 0.843). Although plasma brain natriuretic peptide level was not correlated with HRV, plasma
norepinephrine level was moderately well correlated with the total low- to high-frequency ratio of HRV
(r = 0.529).
Conclusions: SAS screening is important for heart failure patients, because absence of subjective
sleepiness is not reliable in ruling out SDB. The SAS screening with SD-101 might apply for managing
heart failure.
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Despite recent advances in the management of heart failure,
mortality rates in heart failure patients remain high [1]. Heart
failure is a global epidemic in health care and a leading cause of
mortality and morbidity worldwide [2]. In Japan an estimated
1.0 million individuals have heart failure [3,4] and the number of
Japanese outpatients with left ventricular (LV) dysfunction is* Corresponding author at: Department of Advanced Medicine in Cardiopulmo-
nary Disease, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho,
Shouwa-ku, Nagoya 466-8550, Japan. Tel.: +81 52 744 0388; fax: +81 52 744 0388.
E-mail address: hirasiki@med.nagoya-u.ac.jp (A. Hirashiki).
http://dx.doi.org/10.1016/j.jjcc.2014.12.018
0914-5087/ 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rightspredicted to increase gradually from 979,000 in 2005 to 1.3 million
by 2030 [3].
In acute heart failure, adrenergic activation initially occurs in
response to hemodynamic overload or/and an intrinsic reduction
in pump failure [5]. In addition, obstructive sleep apnea (OSA) and
central sleep apnea (CSA) interfere with neuro-humoral systems
and thus may worsen heart failure by increasing sympathetic and
renin–angiotensin–aldosterone activity [6]. Furthermore, there is a
link between sympathetic overactivity and sleep-disordered
breathing (SDB) [7], and both of which are important indicators
of the development of heart failure [8]. Therefore, assessment of
both SDB and cardiac autonomic nervous system is important for
managing new-onset heart failure or preventing recurrent heart
failure at as early a stage as possible. To manage the increasing reserved.
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SDB and activation of the adrenergic nervous system needs to be as
non-invasive, simple, and cost-effective as possible.
Although complete laboratory technologist-attended polysom-
nography (PSG) remains the accepted standard for evaluation of
SDB [9], such assessments are complicated. The SD-101 sleep
recorder (Kenzmedico Co. Ltd., Saitama, Japan) is a newly
developed type-4 respiratory monitoring device that can be used
to quantify the subject’s respiratory movements and monitor for
SDB under the Japanese medical insurance system. The device uses
an array of pressure sensors embedded in its sheet-shaped core
[10,11]. This device does not restrain the patient with tubes or
cords, and it can be used easily by simply being placed on the bed.
Analysis of heart rate variability (HRV) has been used widely as
a reliable tool for evaluating cardiovascular autonomic control in
health and disease [12]. The Cardy 303 pico (Suzuken Co. Ltd.,
Nagoya, Japan) is one of the world’s smallest and lightest
(W 28  D 42  H 9 mm, 13 g) Holter monitors used for this
purpose.
Here, we used these two novel devices—the SD-101 and the
Cardy 303 pico—as screening tools to check for SDB and assess the
autonomic nervous system in patients with acute decompensated
heat failure (ADHF) who were in a stable condition after
appropriate medical treatment. To our knowledge, this is the ﬁrst
study to use these novel devices simultaneously to screen for SDB
and assess the autonomic nervous system in patients with
heart failure. The purpose of this study is to assess screening of
SDB and the autonomic nervous system by these non-invasive and
minimally restrictive methods in ADHF patients.
Methods
Study design and ethical considerations
Forty-nine patients hospitalized for worsening heart failure
were enrolled in the study. We excluded patients with atrial
ﬁbrillation, implanted pacemakers, or dementia. When all patients
had been stabilized after appropriate medical treatment, they
underwent laboratory measurements [including plasma brain
natriuretic peptide (BNP) and norepinephrine], echocardiography,
24-h Holter electrocardiography (ECG) with the Cardy 303 pico,
and a sleep study for sleep apnea syndrome (SAS) screening with
the SD-101. We assessed daytime sleepiness by using the Epworth
Sleepiness Scale (ESS) [13]. The Ethical Review Board of Nagoya
University School of Medicine approved the study protocols. All
patients provided written informed consent with regard to the
study procedures and potential risks.
Sleep testing
The SD-101 is a newly developed type-4 portable respiratory
monitor with a sheet-like shape approved under the Japanese
government medical insurance system, as previously described
[14]. Respiratory events were deﬁned as a 50% decrease in
respiratory effort waveforms lasting >10 s from the preceding
baseline value. We deﬁned the respiratory disturbance index (RDI)
obtained from the SD-101 data as the number of respiratory events
divided by the amount of time spent in bed, because total sleep
time could not be estimated from the SD-101 data alone. The
deﬁnition of moderate to severe SDB using the RDI parameter
was set to 15 events/h.
HRV
On the same day as they underwent the SD-101 sleep test,
all patients underwent Holter electrocardiography. HRV wasanalyzed by using the Cardy Analyzer 05 electrocardiogram data
viewer (Suzuken Co. Ltd., Nagoya, Japan), as previously described
[15]. HRV was assessed by examining the R–R interval in the
time-domain analysis and the power spectral analysis. Hayano
et al. [16,17] have reported that the cyclic variation of heart rate
(CVHR) index obtained by using the autocorrelated wave
detection with adaptive threshold (ACAT) algorithm is closely
correlated with the apnea–hypopnea index (AHI) and shows good
performance in identifying patients with moderate-to-severe
OSA. The ACAT algorithm is a time-domain method that uses only
interbeat interval data. The processes of the ACAT algorithm were
as follows: Interbeat interval time series were smoothed by
second-order polynomial ﬁtting, and all dips in the smoothed
trend with widths between 10 and 120 s and depth-to-width
ratios of >0.7 ms/s were detected. Also, the upper and lower
envelopes of the interbeat interval variations were calculated as
the 95th and 5th percentile points, respectively, within a sifting
window with a width of 130 s. Then, the dips that met the
following criteria were considered CVHR: (1) a depth >40% of the
envelope range at that point (adaptive threshold), (2) interdip
intervals (cycle length) between 25 and 130 s, (3) a wave form
similar to those of the two preceding and two subsequent dips
with a mean morphological correlation coefﬁcients >0.4 (auto-
correlated wave), and (4) three cycle lengths between four
consecutive dips that meet the following equivalence criteria:
(3  2l1/s)(3  2l2/s)(3  2l3/s) > 0.8, where l1, l2, and l3 are three
consecutive cycle lengths and s = (l1 + l2 + l3)/3 [16]. The algo-
rithm of CVHR has been incorporated into the data obtained
with a Holter ECG scanner before [17].
In the power spectral analysis, the low-frequency (LF) and high-
frequency (HF) components of HRV in the daytime (9 AM to 9 PM)
and at night (midnight to 6 AM) and for the total period were
calculated for each subject. Spectral measures were computed by
using the fast-Fourier transform method. A component band in
the frequency range from 0.04 to 0.15 Hz was considered an LF
component. A component band in the frequency range from 0.15
to 0.40 Hz was considered an HF component.
Statistical analysis
Data are presented as means  standard deviation (SD). Contin-
uous variables were compared between two groups with the use of
Student’s t-test for unpaired data. Categorical variables are presented
as numbers (percentages), and were performed by a Fisher exact test.
BNP, LF, and HF were naturally logarithmically transformed to
approximately normalize the distribution and then used in the
analysis. A Pearson product moment correlation analysis method was
used to assess correlations between continuous variables. Pre-
speciﬁed subgroups were deﬁned by gender; cut-off values for
median age (70 years), body mass index (25 kg/m2), plasma BNP
(200 pg/ml), and left ventricular ejection fraction (50%); initial or
repeat hospitalization for worsening heart failure; presence or
absence of ischemic heart disease; and presence or absence of
diabetes. All analyses were performed with the SPSS 21.0 software
package (SPSS/IBM, Chicago, IL, USA). A p-value of <0.05 was
considered statistically signiﬁcant.
Results
Baseline characteristics of patients are shown in Table 1. The
group included 24 (49.0%) patients with age 70 years, 16 (32.7%)
with BMI 25 kg/m2, 31 (63.3%) with plasma BNP level 200 pg/ml,
and 40 (81.6%) with an LV ejection fraction <50%. The frequency
distribution of the RDI in 5-unit intervals for the 49 (male 38, female
11) heart failure patients is depicted in Fig. 1. SDB was present in
47 of our ADHF patients (95.9%); only 4.1% of patients did not present
Table 1
Baseline characteristics.
All (n = 49)
Age (years) 66.8  14.8
Gender (male, %) 38 (77.6%)
BMI (kg/m2) 24.0  4.7
Systolic blood pressure (mm Hg) 116.4  18.5
Diastolic blood pressure (mm Hg) 66.2  13.7
NYHA functional class (I/II/III/IV) 5/19/18/7
Hypertension (n, %) 33 (67.3%)
Diabetes (n, %) 20 (40.8%)
Ischemic heart disease (n, %) 19 (38.8%)
Previous hospitalization for heart failure (n, %) 17 (34.7%)
Smoking (n, %) 7 (14.3%)
RDI (/h) 21.9  11.4
RDI (5; n, %) 47 (95.9%)
RDI (15; n, %) 35 (71.4%)
CVHRI (/h) 18.1  14.0
ESS 4.06  3.29
ESS (11; n, %) 4 (8.2%)
Medication
Diuretics (n, %) 45 (91.8%)
Beta-blockers (n, %) 31 (63.3%)
ACE inhibitors or ARBs (n, %) 42 (85.7%)
Digitalis (n, %) 5 (10.2%)
Aldosterone antagonists (n, %) 30 (61.2%)
Laboratory measurements
Hemoglobin (mg/dl) 12.7  2.7
Creatinine (mg/dl) 1.37  0.71
Estimated GFR (ml min1 1.73 m2) 49.4  23.2
HbA1c (%) 6.46  1.27
Plasma BNP (pg/ml) 392  394
Plasma norepinephrine (ng/ml) 0.575  0.328
Echocardiography
LVDd (mm) 61.9  9.2
LVDs (mm) 49.8  10.6
IVS (mm) 9.7  2.1
LVPW (mm) 9.5  2.0
LVEF (%) 40.1  13
LV mass index (g/m2) 188.1  52.6
Heart rate variability
Heart rate (beats/min) 75.1  10.3
Daytime LF (ln-ms2) 4.57  1.39
Night-time LF (ln-ms2) 4.80  1.40
Total LF (ln-ms2) 4.89  1.35
Daytime HF (ln-ms2) 4.06  1.29
Night-time HF (ln-ms2) 4.28  1.37
Total HF (ln-ms2) 4.33  1.29
Daytime LF/HF ratio 2.27  2.03
Night-time LF/HF ratio 2.48  2.36
Total LF/HF ratio 2.51  2.24
BMI, body mass index; NYHA, New York Heart Association; RDI, respiratory
disturbance index; CVHRI, cyclic variation of heart rate index; ESS, Epworth
Sleepiness Scale; ACE, angiotensin-converting enzyme; ARB, angiotensin-
receptor blocker; GFR, glomerular ﬁltration rate; BNP, brain natriuretic peptide;
LV, left ventricle; LVDd, LV diastolic diameter; LVDs, LV systolic diameter; IVS,
intraventricular septal thickness; LVPW, LV posterior wall thickness; LVEF, LV
ejection fraction; SDNN, standard deviation of the N–N interval; LF, low
frequency; HF, high-frequency.
Fig. 1. Distribution of respiratory disturbance index (RDI) values among males and
females. The frequency distribution of RDI in 5-unit intervals in male (hatched
boxes) and female (clear boxes) patients is shown.
Fig. 2. Correlation between respiratory disturbance index (RDI) and cyclic variation
of heart rate index (CVHR index). The graph shows the correlation between RDI
using the SD-101 system (Kenzmedico Co. Ltd., Saitama, Japan) and CVHR index
from nocturnal data as analyzed by using the Cardy Analyzer 05 (Suzuken Co. Ltd.,
Nagoya, Japan).
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(5 events/h  RDI < 15 events/h) was present in 24.5% of all
patients, and 71.4% of patients had moderate to severe SDB (RDI
of 15 events/h). Among males, 30 (78.9%) had moderate to severe
SDB (RDI 15 events/h), with a mean RDI of 24.5 events/h. Among
females, 5 (45.5%) had moderate to severe SDB (RDI 15 events/h),
with a mean RDI of 13.0 events/h.
We examined the relationship between RDI on SD-101 testing
and CVHR index from nocturnal data (Fig. 2). RDI was closely
correlated with CVHR index (r = 0.843, p < 0.001). We also
examined the relationship between RDI and ESS score. RDI was
not associated with ESS score (p = 0.568, data not shown). Four
(8.2%) patients had ESS scores 11, which is generally deﬁned asdaytime sleepiness. Two of these patients (50%) had RDI
15 events/h on SD-101 testing. The relationships among plasma
norepinephrine, RDI, plasma BNP, and components of HRV were
examined (Table 2). Plasma norepinephrine level was positively
correlated with RDI and negatively correlated with the HF
component of HRV. In addition, plasma norepinephrine level
was positively correlated with the LF/HF ratio. RDI was correlated
with only the daytime HF component of HRV (r = 0.287,
p = 0.046), but only slightly. Plasma BNP level was not correlated
with plasma norepinephrine level, RDI, or any of the measured
components of HRV.
We classiﬁed subgroups according to the baseline character-
istics mentioned in the Methods section. We then compared RDI,
total LF/HF ratio, and the total HF component of HRV among the
Table 2
Correlations among plasma norepinephrine level, respiratory disturbance index (RDI), plasma brain natriuretic peptide (BNP) level, and components of heart rate variability.
Norepinephrine RDI ln BNP
r p-Value r p-Value r p-Value
Daytime LF (ln-ms2) 0.195 0.19 0.192 0.187 0.038 0.798
Night-time LF (ln-ms2) 0.125 0.402 0.075 0.607 0.125 0.393
Total LF (ln-ms2) 0.095 0.523 0.054 0.711 0.098 0.504
Daytime HF (ln-ms2) S0.341 0.019 S0.287 0.046 0.153 0.294
Night-time HF (ln-ms2) S0.382 0.008 0.205 0.158 0.043 0.770
Total HF (ln-ms2) S0.376 0.009 0.205 0.158 0.056 0.701
Daytime LF/HF ratio 0.295 0.044 0.099 0.497 0.243 0.092
Night-time LF/HF ratio 0.467 0.001 0.123 0.401 0.182 0.211
Total LF/HF ratio 0.529 <0.001 0.133 0.361 0.201 0.165
ln BNP 0.244 0.099 0.053 0.719 – –
RDI 0.296 0.043 – – – –
LF, low frequency; HF, high-frequency.
Signiﬁcance of bold value is p < 0.05.
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females (24.5  11.2 events/h vs. 13.0  6.2 events/h, p < 0.001).
Males and younger patients (<70 years) tended to have higher total
LF/HF ratios than females and patients 70 years (2.80  2.44 vs.
1.51  0.89, p = 0.09; 3.11  2.03 vs. 1.88  2.33, p = 0.05, respec-
tively). Older patients (70 years) had signiﬁcantly higher total HF
components than younger patients (4.71  1.27 ln-ms2 vs.
3.97  1.23 ln-ms2, p = 0.04), and patients with ischemic heart
disease or diabetes tended to have higher total HF components
than patients without these diseases (4.81  1.52 ln-ms2 vs.Fig. 3. Comparison of respiratory disturbance index (RDI), total low frequency (LF) to hig
RDI, total LF/HF ratio, and total HF were compared in pre-speciﬁed subgroups for age (7
presence of recurrent heart failure or new (Recurrent, New onset), presence or absence of
natriuretic peptide level (BNP; 200 or <200 pg/ml), and left ventricular ejection fract4.03  1.05 ln-ms2, p = 0.05; 4.78  1.49 ln-ms2 vs. 4.03  1.06
ln-ms2, p = 0.06, respectively).
Discussion
Our major ﬁndings were as follows: (1) the frequency of
occurrence of an abnormal RDI on SD-101 screening for SAS was
high, especially in men; (2) there was no relationship between RDI
and ESS score; and (3) many of the components of HRV were
correlated with plasma norepinephrine level, but not with plasmah frequency (HF) ratio of heart rate variability, and total HF score in key subgroups.
0 or <70 years), gender, obesity [body mass index (BMI) 25 kg/m2 or <25 kg/m2],
 ischemic heart disease (IHD), presence or absence of diabetes mellitus, plasma brain
ion (LVEF; <50% or 50%).
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that assessment of SDB by portable respiratory monitoring with
the novel SD-101 device for sleep apnea screening and of the
autonomic nervous system by using HRV provides important
information of clinical relevance, as discussed below. This
information should be useful for managing heart failure and
preventing its recurrence.
RDI assessment in screening
Recent data suggest that sleep apnea can lead to the
progression of cardiac dysfunction in patients with chronic
heart failure [17]. This adverse effect on cardiac function
probably arises from repetitive apneas causing arterial oxyhe-
moglobin desaturation and excessive stimulation of the sympa-
thetic nervous system [17,18]. Javaheri et al. [19] reported that
moderate to severe SDB (RDI 15 events/h) was present in 51%
(40% CSA and 11% OSA) of male patients with stable heart failure,
and Oldenburg et al. [20] showed that it was present in 76% of
patients (40% CSA and 36% OSA) with symptomatic chronic heart
failure. The relative occurrence rates of both CSA and OSA are
signiﬁcantly greater in men than in women [21]. In accordance
with these previous ﬁndings [19–21], the distribution of RDI
differed between males and females in our study. The prevalence
of moderate to severe SDB (RDI 15%) was 78.9% in our males
and 45.5% in our females. Notably, there were no female heart
failure patients with RDI 25/h.
We used a novel non-restrictive device, the SD-101, which
corresponds to a type-4 measurement device, and a new, small
Holter monitor, the Cardy 303 pico. The RDI values obtained by
SD-101 testing were strongly correlated with the CVHR index
values obtained by using the Cardio 303 pico as shown in Fig. 2. In
accordance with the present study, Hayano et al. [16] demonstrat-
ed that CVHR index values obtained by using the ACAT algorithm
on Holter monitoring were closely correlated with the AHI
obtained by using PSG (r = 0.95). Furthermore, Agatsuma et al.
[14], in time-matched comparisons, revealed that RDI, as measured
by SD-101, and the apnea–hypopnea index (AHI), as calculated by
PSG, were closely correlated. This is the ﬁrst study to show the
correlation between RDI by SD-101 and CVHR index. The SD-101
system can be used as a new screening tool for sleep apnea under
the Japanese government medical insurance system and is
therefore useful for SAS screening in heart failure patients. Given
the fact that the number of Japanese heart failure patients is
predicted to increase gradually, we consider that this accuracy of
RDI by SD-101 is acceptable to be used for SAS screening from the
present study and the previous studies [14,16]. However, once
the patient is suspected to have SDB, additional PSG test should
be performed.
ESS is a standard tool for assessing daytime sleepiness and is
signiﬁcantly correlated with the AHI in subjects without heart
failure [13]. On the other hand, Arzt et al. [22] found that the ESS
score was not associated with RDI in heart failure patients in
agreement with our ﬁndings. Therefore, heart failure patients are
likely to be a high-risk group for the presence of SDB, regardless of
the presence or absence of daytime sleepiness. Because of its non-
invasive and non-restrictive nature, the SD-101 device should be
especially useful for SAS screening in those heart failure patients
who are of advanced age or of nervous disposition and may be
unwilling to accept restrictive examinations.
HRV in patient subgroups
Heterogeneous pathophysiologies underlie heart failure, and
patients with heart failure have many comorbidities or conditions.
Our patients included those with hypertension (67.3%), ischemicheart disease (38.8%), and normal (50%) left ventricular ejection
fraction (18.4%). We therefore analyzed the status of the
autonomic nervous system among subgroups based on the
baseline characteristics. Although the power of HRV is decreased
in diabetes patients [23], we found that the HF component alone
tended to be higher in patients with diabetes than in non-diabetics.
Similarly, the power of HRV is decreased in patients with severe
heart failure [24–26], but we found no signiﬁcant differences in
total LF/HF ratio or total HF component among subgroups
categorized according to BNP, left ventricular ejection fraction,
and new-onset or recurrent heart failure. In the previous studies,
AHI is inﬂuenced by age and obesity [9], and HRV is inﬂuenced by
age, diabetes, and severity of heart failure [27]. Unfortunately, the
association between RDI by SD-101 and autonomic nervous
system was weak as shown in Table 2 and Fig. 3. The reason
might be small sample size, heterogeneous pathophysiology, and
many comorbidities in this population. Further studies with larger
numbers of patients are needed to conﬁrm our results.
Clinical implications of assessment of both SDB and autonomic
dysfunction
Previous studies have shown that approximately 50% of heart
failure patients have SAS [19,21]. Deﬁnitive diagnosis of OSA
requires all-night laboratory PSG, which is hard to perform in many
patients because of the substantial cost and inconvenience.
Accordingly, simple and efﬁcient screening methods are needed
to identify patients with a high probability of having SDB.
Treatment of coexisting OSA by continuous positive airway
pressure (CPAP) improves left ventricular systolic function [28].
Adaptive servo ventilation (ASV) and CPAP also to some extent
improved nocturnal breathing pattern and sleep quality in patients
with CSA in heart failure [29]. CPAP and ASV are important in order
to stabilize the autonomic nervous systems [30,31]. Exercise
inﬂuences autonomic nervous system and respiratory status
[32,33]. Taken together, these new screening devices may be
useful especially for obesity, male, and hypertensive heart failure
patients because such patients often have SAS or autonomic
dysfunction. In the future, the new non-restrictive and less onerous
portable monitor devices that we used here as screening tools will
be useful for evaluating autonomic dysfunction, including SDB, at
home in patients with stage B or C heart failure.
Our study had several limitations. First, SD-101 testing could
not distinguish between OSA and CSA because it uses a type-4
respiratory monitoring device. As we have already stated, once the
patient is suspected to have SDB, additional PSG test should be
performed. Further investigations using the full PSG to assess
SAS accurately are desired. Second, several patients were taking
beta-blockers as medical treatment for their heart failure at the
time of enrollment. Recent studies have shown that beta-blockers
change the autonomic nerve balance in patients with heart failure
[34] and may thus affect the values in SDB or HRV testing. Third,
our small sample size might have limited our ability to prove the
relationship between SDB, the autonomic nervous system, and
plasma BNP levels. A larger study is required to investigate this
relationship further. To assess HRV simultaneously with SDB,
we had to exclude patients with atrial ﬁbrillation or implanted
pacemakers. The prevalence of these comorbidities is increasing in
heart failure patients, but patients who have them cannot receive
HRV testing together with SDB screening.
Conclusions
Because the frequency of occurrence of abnormal RDI is high
and absence of subjective sleepiness is not a reliable means of
ruling out SDB, screening by respiratory monitoring is important in
S. Shimazu et al. / Journal of Cardiology 66 (2015) 218–223 223evaluating sleep apnea–related pathophysiology in patients with
heart failure. The SAS screening with SD-101 could help to detect
the potential SDB and apply for heart failure patients in routine
clinical practice. This study population is small, and therefore,
large conﬁrmatory studies are needed.
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